Background: The aim of this study was to investigate the impact of the high-dose regimen on the outcome of patients with follicular lymphoma (FL) having had autologous stem-cell transplantation (ASCT) in a recent time period.
concerns arising from studies in the pre-rituximab era about an increased non-relapsed mortality (NRM) in TBI-treated patients due to a higher incidence of treatment-related myelodysplastic syndromes/acute myelogenous leukaemia (t-MDS/AML) in comparison with patients treated with chemotherapy-based conditioning regimens [7, 12] . This had led to a shift in many centres to chemotherapy-based regimens, although there has never been a prospective study comparing TBI and non-TBI HDT regimens in patients with FL. However, since these concerns are largely based on studies from the 1980s and early 1990s, it is unknown if the detrimental TBI effect is valid in more recent populations, given the fact that transplant and irradiation methodology has developed and also t-MDS/AML-relevant variables independent from transplantation, such induction and salvage chemotherapy, may have changed over time.
The primary aim of the present study was to compare the outcome of ASCT in patients with FL who received TBI-based HDT with those who received standard high-dose chemotherapy with carmustin, etoposide, cytarabine and melphalan (BEAM) from 1995 onwards.
patients and methods
data source
EBMT is a voluntary organization comprising >600 transplant centres mainly from Europe. Accreditation as a member centre requires submission of minimal essential data (MED-A form) from all consecutive patients to a central registry in which patients may be identified by the diagnosis of underlying disease and type of transplantation. MED-A data are updated annually. Informed consent for transplantation and data collection was obtained locally according to regulations applicable at the time of transplantation. Since 1 January 2003, all transplant centres have been required to obtain written informed consent before data registration with the EBMT following the Helsinki Declaration 1975.
patient eligibility
Eligible for this registry study were patients with FL aged 18 years or older who underwent a first ASCT after HDT with TBI or BEAM from 1995 to 2007 and were registered with the EBMT before March 2011 with a full dataset as required for this analysis. Patients with histological transformation at the time of HDT/ASCT were excluded as well as those undergoing a second transplant.
remission status categorization
For the purpose of this analysis, primary refractory disease, refractory and untreated relapse, stable disease, and progressive disease were grouped together as active disease. First complete response (CR1), first partial response (PR1) and first very good PR were grouped together as first remission (remission 1). Subsequent CR or PR were grouped together as subsequent remission (remission >1).
outcome measures
Overall survival (OS) was measured from the time of HDT/ASCT to death from any cause. Event-free survival (EFS) was measured from the time of HDT/ASCT to progression, reoccurrence of the disease, or death from any cause. NRM was defined as death from any cause without progression. Figure S1 , available at Annals of Oncology online). Moreover, in the TBI group, significantly more patients had been autografted within the first year after diagnosis, were in first remission at HDT/ASCT, and were transplanted within a trial protocol whereas, in the BEAM group, the proportion of patients with documented MoAb exposure was significantly higher (Table 1) . Figure 1A ). On multivariate analysis increasing age, time from diagnosis to HDT/ASCT >1 year, no documented previous MoAb treatment, and BM as the source of stem cells but not the HDT regimen used were significant predictors of an increased NRM (Table 2) . With a median interval from HDT/ASCT of 68 and 58 months, secondary neoplasms were reported for 66 (9.7%) and 123 (7.9%) patients of the TBI and BEAM groups, respectively (P = 0.19). Type of secondary malignancy was t-MDS/AML in 36% and 38%, other haematological neoplasm in 13% and 13%, and solid tumour in 50% and 47% after TBI and BEAM. Overall, the frequency of t-MDS/AML was 3.4% after TBI and 2.8% after BEAM (P = 0.57), and the median time interval from transplant to t-MDS/AML 51 [interquartile range (IQR) 29-75] and 49 (IQR 34-67) months after transplant (P = 0.44).
non-relapse mortality

incidence of relapse
With a median follow-up of survivors of 73 months (IQR 30-107), the 5-year IR of all patients was 42% (95% CI 40% to 44%). The 5-year IR was significantly lower in patients treated with TBI (35%, 95% CI 31% to 39%) compared with BEAM (45%, 95% CI 42% to 48%, P < 0.001). In addition, on univariate analysis, patients transplanted with active disease were more likely to relapse than patients transplanted in first remission. On multivariate analysis, patients treated with BEAM had a significantly increased relapse risk compared with patients treated with TBI (Table 2) .
event-free survival
The median EFS for the whole group was 67 months, with a 5-year EFS of 52% (95% CI 49% to 54%). On univariate analysis, patients who had BEAM HDT had significantly shorter EFS than patients who received TBI (5-year estimate: 49%, 95% CI 46-52 versus 58%, 95% CI 54-62; P < 0.001) ( Figure 1B) . Patients who had received documented previous MoAb treatment had a longer EFS than patients that did not (5-year EFS: 56%, 95% CI 52% to 61% versus 50%, 95% CI 47% to 53%, P = 0.009) (supplementary Figure S2 , available at Annals of Oncology online). On multivariate analysis stratified for gender, the following factors retained significance and predicted shorter EFS: BEAM HDT, increasing age, no previous MoAb treatment documented, sensitive relapse or active disease at HDT/SCT, and BM as source of stem cells (Table 2) .
overall survival
The median OS for the study population was 193 months. The 5-year OS was 75% (95% CI 73% to 77%) for the whole group. On univariate analysis, BEAM HDT was associated with a significantly shorter OS than TBI-based HDT (5-year estimate: 74%, 95% CI 71-76 versus 77%, 95% CI 74-81; P = 0.042) ( Figure 1C ). In addition, patients with documented previous MoAb exposure had a longer OS than those without (5-year OS: 79%, 95% CI 76% to 82% versus 74%, 95% CI 71% to 75%, respectively, P = 0.014) (supplementary Figure S2 , available at Annals of Oncology online). On multivariate analysis stratified for gender the following factors predicted a significantly shorter OS: increasing age, no documented previous MoAb treatment, time from diagnosis to HDT/ASCT>1 year, active disease at the time of transplantation and BM as the source of stem cells (Table 2) . Moreover, patients undergoing TBI-based HDT had a 0.9 relative risk of dying compared with the BEAM group; however, this difference did not reach statistical significance (P = 0.089).
subset analysis
The favourable effect of TBI on EFS and RI was retained when the analysis was restricted to those 713 patients with documented MoAb exposure, and adjusted for age, gender, time from diagnosis, graft source, and remission status at ASCT (supplementary Figure S3 , available at Annals of Oncology online). Next, multivariate subgroup analyses were carried out separately for patients transplanted in first remission and for those transplanted in subsequent remissions (supplementary Figure S4 , available at Annals of Oncology online), demonstrating that, in remission 1, EFS and IR were significantly better with TBI. However, in the remission >1 subset, a significant TBI benefit could not be documented with the relatively low patient number available (only 115 patients with TBI). Finally, TBI remained a significant predictor of favourable IR and EFS when trial participation was taken into account (supplementary Figure S5 , available at Annals of Oncology online). Significant differences in NRM were not found in any subset.
discussion
The type of high-dose regimen had a significant impact on the relapse risk in our study. Patients receiving a TBI regimen were less likely to relapse and had better EFS on multivariate analysis in comparison to patients treated with the BEAM regimen. The reduced IR in our study is consistent with the results of a previous EBMT study in the pre-rituximab era that also concluded that patients receiving TBI condition were less likely to relapse than those who received a non-TBI-based conditioning regimen [7] . A study by Darrington et al. also suggested an improved failure-free survival following HDT/ASCT in patients receiving a TBI-based conditioning regimen [12] . However, the increased risk of development of t-MDS/AML in patients treated with TBI conditioning outweighed the benefit of an improved IR in both of the above studies. NRM due to t-MDS/AML is a well-acknowledged complication of HDT/ASCT for FL or other lymphoma [13] . Since the late 1990s, there is concern that TBI may be associated with an increased risk of t-MDS/AML. This notion is largely based on three retrospective studies assessing the t-MDS/AML risk in transplants carried out before 1995, one of them the ancestor study to the present analysis [7, 12, 14] . In contrast to this previous study from the EBMT, where an increased NRM in TBItreated patients started to emerge from 5 years after transplant onward [7] , in our present study, both groups of patients had a similar NRM over the whole observation time. One explanation for this discrepancy could be a matter of follow-up, which was twice as long in the preceding study compared with the present one. However, the median time to t-MDS/AML development after HDT/ASCT is consistently reported to be 5 years or less, with the bulk of cases occurring within 10 years [7, 12, 13, 15] . Since >50% of the TBI-treated patients in this study have an observation time which is longer than 5 years and 25% longer than 9 years, late excess NRM due to t-MDS/AML in the TBI cohort should tend to become visible if existent. Indeed, the median time to t-MDS/AML in the present study was around 4 years in both groups with no significant difference in t-MDS/AML frequency. This finding is in keeping with the results of Tarella et al., who did not find an elevated t-MDS/AML risk in patients with FL having received TBI between 1985 and 2005 [15] .
Moreover, the TBI and BEAM groups were heavily imbalanced for many variables potentially predicting outcome. Nonetheless, the observed effects of TBI HDT on NRM remained stable even after multivariate adjustment for confounding factors including remission status at ASCT and also in subset analyses restricted to rituximab exposure, disease status at transplant, and trial participation. Accordingly, the reasons for the lower late NRM after TBI HDT in the present study compared with the 1979-1985 series (6% and 10% versus 11% and 16% at 5 and 10 years, respectively) [7] remain speculative. Apart from unrecognized confounders they might include advances in transplant methodology (e.g. use of peripheral blood instead of marrow stem cells) and also irradiation technology [16] . Moreover, t-MDS/AML-relevant variables independent from transplantation, such as induction and salvage chemotherapy, may have changed over time and thereby contributed to the decrease in late NRM observed after TBI HDT here [17] .
The absence of a detrimental effect of pre-transplant rituximab on the relapse risk is in keeping with previous smaller retrospective studies [18, 19] . The current study, with a larger number of patients, confirms that HDT/ASCT remains an excellent salvage option in patients previously treated with immuno-chemotherapy. Nevertheless, further studies will need to evaluate the outcome of patients relapsing after having received maintenance with rituximab.
This study has some limitations inherent to a registry study. Moreover, whereas the follow-up is relatively long, it might not be long enough to draw firm conclusions on late toxicity and secondary malignancies. In addition, there are some missing data with potential prognostic importance, such as the number of treatment lines or the number of relapses before HDT/ASCT.
In summary, in patients with FL who received HDT/ASCT after 1995 for FL TBI was not associated with increased risks of t-MDS/AML and NRM if compared with BEAM, while disease control is at least equivalent to that of BEAM. These results are setting the stage for re-assessing the value of radiotherapy-based HDT in those indications where ASCT continues to be appropriate in the current CD20 MoAb era [10, 11] and in the upcoming targeted treatment landscape [20] . In the absence of prospective randomized trials, selection of the HDT regimen might be based on general criteria, such as centre experience and availability of TBI, and on individual factors, such as doselimiting pre-irradiation and intolerance to certain HDT drugs. There is also some rationale for preferring TBI in patients with less chemosensitive disease although formal evidence supporting such a policy is lacking.
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